Gresham Richter
Concepts (598)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vascular Malformations | 25 | 2025 | 105 | 7.830 |
Why?
| | Arteriovenous Malformations | 19 | 2024 | 74 | 7.510 |
Why?
| | Hemangioma | 16 | 2025 | 86 | 6.180 |
Why?
| | Propranolol | 11 | 2025 | 76 | 3.890 |
Why?
| | Glottis | 9 | 2024 | 34 | 3.730 |
Why?
| | Laryngomalacia | 10 | 2024 | 25 | 3.630 |
Why?
| | Lymphatic Abnormalities | 7 | 2020 | 20 | 2.940 |
Why?
| | Infant | 56 | 2025 | 3709 | 2.510 |
Why?
| | Neck | 12 | 2022 | 97 | 2.120 |
Why?
| | Child | 61 | 2025 | 7194 | 2.060 |
Why?
| | Child, Preschool | 49 | 2025 | 4046 | 2.000 |
Why?
| | Sclerotherapy | 12 | 2023 | 47 | 1.850 |
Why?
| | Humans | 135 | 2025 | 52441 | 1.840 |
Why?
| | Lasers, Solid-State | 5 | 2020 | 30 | 1.780 |
Why?
| | Treatment Outcome | 39 | 2025 | 5508 | 1.700 |
Why?
| | Laryngoscopy | 10 | 2020 | 59 | 1.680 |
Why?
| | Ambulatory Surgical Procedures | 3 | 2024 | 52 | 1.670 |
Why?
| | Deglutition Disorders | 5 | 2017 | 76 | 1.660 |
Why?
| | Laryngostenosis | 4 | 2020 | 11 | 1.660 |
Why?
| | Laser Therapy | 6 | 2020 | 74 | 1.480 |
Why?
| | Laryngoplasty | 2 | 2024 | 8 | 1.470 |
Why?
| | Male | 81 | 2025 | 26874 | 1.370 |
Why?
| | Vascular Surgical Procedures | 5 | 2020 | 166 | 1.360 |
Why?
| | Embolization, Therapeutic | 8 | 2023 | 93 | 1.310 |
Why?
| | Otolaryngology | 6 | 2025 | 62 | 1.310 |
Why?
| | Female | 79 | 2025 | 28277 | 1.290 |
Why?
| | Larynx | 7 | 2017 | 30 | 1.210 |
Why?
| | Tonsillectomy | 4 | 2021 | 50 | 1.210 |
Why?
| | Veins | 6 | 2023 | 74 | 1.200 |
Why?
| | Hemangioma, Capillary | 2 | 2020 | 12 | 1.170 |
Why?
| | Retrospective Studies | 35 | 2024 | 6694 | 1.150 |
Why?
| | Head | 6 | 2022 | 70 | 1.100 |
Why?
| | Skin | 7 | 2020 | 416 | 1.000 |
Why?
| | Trachea | 5 | 2018 | 55 | 0.880 |
Why?
| | Head and Neck Neoplasms | 6 | 2015 | 289 | 0.880 |
Why?
| | Heart Bypass, Right | 1 | 2024 | 13 | 0.870 |
Why?
| | Arteriovenous Fistula | 1 | 2024 | 27 | 0.860 |
Why?
| | Blood Proteins | 1 | 2024 | 84 | 0.850 |
Why?
| | Pulmonary Veins | 1 | 2024 | 42 | 0.850 |
Why?
| | Adolescent | 31 | 2024 | 6713 | 0.840 |
Why?
| | Facial Neoplasms | 2 | 2017 | 22 | 0.830 |
Why?
| | Tongue | 4 | 2023 | 41 | 0.830 |
Why?
| | Fontan Procedure | 1 | 2024 | 66 | 0.830 |
Why?
| | Vocal Cord Paralysis | 2 | 2022 | 23 | 0.820 |
Why?
| | Pulmonary Artery | 2 | 2024 | 142 | 0.820 |
Why?
| | Collagen | 4 | 2019 | 215 | 0.820 |
Why?
| | Surgery, Computer-Assisted | 3 | 2020 | 54 | 0.820 |
Why?
| | Otorhinolaryngologic Diseases | 2 | 2014 | 11 | 0.810 |
Why?
| | Cell Proliferation | 7 | 2023 | 1013 | 0.800 |
Why?
| | Infant, Newborn | 20 | 2024 | 2871 | 0.770 |
Why?
| | Proteome | 1 | 2024 | 175 | 0.770 |
Why?
| | Face | 2 | 2020 | 56 | 0.770 |
Why?
| | Health Information Systems | 1 | 2022 | 18 | 0.760 |
Why?
| | Respiratory Aspiration | 2 | 2014 | 8 | 0.750 |
Why?
| | Nitric Oxide Synthase Type III | 3 | 2013 | 83 | 0.750 |
Why?
| | Adrenergic beta-Antagonists | 4 | 2020 | 107 | 0.740 |
Why?
| | Hyperpigmentation | 1 | 2021 | 10 | 0.730 |
Why?
| | Proteomics | 1 | 2024 | 332 | 0.720 |
Why?
| | Cricoid Cartilage | 2 | 2020 | 10 | 0.720 |
Why?
| | Receptors, Progesterone | 1 | 2021 | 68 | 0.680 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 3 | 2014 | 34 | 0.680 |
Why?
| | Ambulatory Care Facilities | 1 | 2021 | 122 | 0.670 |
Why?
| | Graft Survival | 4 | 2011 | 157 | 0.670 |
Why?
| | Intracranial Arteriovenous Malformations | 2 | 2019 | 31 | 0.670 |
Why?
| | Dermatologic Surgical Procedures | 1 | 2020 | 35 | 0.660 |
Why?
| | Receptors, Estrogen | 1 | 2021 | 133 | 0.660 |
Why?
| | Dilatation | 2 | 2017 | 27 | 0.660 |
Why?
| | Prospective Studies | 9 | 2022 | 2433 | 0.650 |
Why?
| | Risk Assessment | 10 | 2018 | 1349 | 0.640 |
Why?
| | Tracheostomy | 3 | 2022 | 76 | 0.620 |
Why?
| | Vasodilator Agents | 2 | 2017 | 90 | 0.610 |
Why?
| | Inpatients | 1 | 2021 | 203 | 0.610 |
Why?
| | Elastin | 1 | 2019 | 23 | 0.610 |
Why?
| | Follow-Up Studies | 15 | 2018 | 2294 | 0.600 |
Why?
| | Gene Expression Profiling | 3 | 2020 | 1099 | 0.600 |
Why?
| | Skin Transplantation | 3 | 2009 | 43 | 0.600 |
Why?
| | Gastroesophageal Reflux | 2 | 2017 | 50 | 0.600 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2009 | 186 | 0.590 |
Why?
| | Thyroid Cartilage | 1 | 2018 | 3 | 0.580 |
Why?
| | Endothelial Cells | 4 | 2024 | 283 | 0.580 |
Why?
| | Pharynx | 3 | 2014 | 31 | 0.580 |
Why?
| | Vascular Neoplasms | 1 | 2018 | 17 | 0.580 |
Why?
| | Mast Cells | 1 | 2018 | 55 | 0.570 |
Why?
| | Postoperative Complications | 5 | 2024 | 1065 | 0.570 |
Why?
| | Endoscopy | 6 | 2015 | 126 | 0.570 |
Why?
| | Estradiol | 2 | 2018 | 226 | 0.560 |
Why?
| | Endovascular Procedures | 1 | 2020 | 180 | 0.550 |
Why?
| | Ki-67 Antigen | 3 | 2013 | 57 | 0.550 |
Why?
| | Young Adult | 13 | 2024 | 4346 | 0.550 |
Why?
| | Disease Models, Animal | 2 | 2013 | 1483 | 0.540 |
Why?
| | Gene Regulatory Networks | 1 | 2018 | 112 | 0.540 |
Why?
| | Respiratory Tract Infections | 2 | 2020 | 82 | 0.540 |
Why?
| | Adult | 32 | 2024 | 14205 | 0.540 |
Why?
| | Deglutition | 3 | 2014 | 45 | 0.540 |
Why?
| | Rectum | 1 | 2017 | 55 | 0.530 |
Why?
| | Vagina | 1 | 2017 | 46 | 0.520 |
Why?
| | Eosinophilic Esophagitis | 1 | 2017 | 43 | 0.520 |
Why?
| | Receptors, Adrenergic, beta | 1 | 2017 | 44 | 0.520 |
Why?
| | Renin-Angiotensin System | 1 | 2017 | 58 | 0.520 |
Why?
| | Laryngeal Neoplasms | 2 | 2015 | 43 | 0.520 |
Why?
| | Ultrasonography, Prenatal | 1 | 2018 | 180 | 0.510 |
Why?
| | Wound Healing | 4 | 2014 | 223 | 0.510 |
Why?
| | Bleomycin | 3 | 2022 | 36 | 0.510 |
Why?
| | Cerebral Palsy | 2 | 2014 | 37 | 0.490 |
Why?
| | Skin Neoplasms | 2 | 2022 | 496 | 0.490 |
Why?
| | Nasopharynx | 2 | 2020 | 34 | 0.490 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2016 | 59 | 0.490 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2016 | 88 | 0.480 |
Why?
| | Sleep Apnea, Obstructive | 2 | 2014 | 70 | 0.470 |
Why?
| | Hearing Aids | 5 | 2017 | 70 | 0.470 |
Why?
| | Blood Coagulation Disorders | 3 | 2020 | 41 | 0.450 |
Why?
| | Blotting, Western | 4 | 2021 | 587 | 0.450 |
Why?
| | Skin Ulcer | 1 | 2014 | 9 | 0.440 |
Why?
| | Alginates | 1 | 2014 | 12 | 0.440 |
Why?
| | Polysaccharides | 1 | 2014 | 58 | 0.430 |
Why?
| | Silver | 1 | 2014 | 48 | 0.420 |
Why?
| | Adenoidectomy | 2 | 2020 | 35 | 0.420 |
Why?
| | Organophosphonates | 1 | 2013 | 6 | 0.420 |
Why?
| | Periodicals as Topic | 1 | 2014 | 63 | 0.410 |
Why?
| | Cytosine | 1 | 2013 | 30 | 0.410 |
Why?
| | Signal Transduction | 3 | 2020 | 1724 | 0.400 |
Why?
| | Sclerosing Solutions | 3 | 2022 | 16 | 0.400 |
Why?
| | RNA, Messenger | 4 | 2022 | 1134 | 0.400 |
Why?
| | Nervous System Diseases | 1 | 2014 | 96 | 0.400 |
Why?
| | Palate | 1 | 2013 | 13 | 0.400 |
Why?
| | Uvula | 1 | 2013 | 13 | 0.400 |
Why?
| | Pharyngeal Diseases | 1 | 2013 | 12 | 0.390 |
Why?
| | Choristoma | 1 | 2013 | 22 | 0.390 |
Why?
| | Infant, Premature, Diseases | 1 | 2013 | 93 | 0.390 |
Why?
| | Thymus Gland | 1 | 2013 | 40 | 0.390 |
Why?
| | Consensus | 5 | 2024 | 195 | 0.390 |
Why?
| | Gestational Age | 2 | 2013 | 415 | 0.390 |
Why?
| | Surgical Flaps | 2 | 2020 | 111 | 0.390 |
Why?
| | Receptors, Cell Surface | 1 | 2013 | 111 | 0.380 |
Why?
| | Comorbidity | 4 | 2024 | 637 | 0.370 |
Why?
| | Quality of Life | 3 | 2014 | 893 | 0.370 |
Why?
| | Milk Hypersensitivity | 1 | 2012 | 19 | 0.370 |
Why?
| | Down Syndrome | 1 | 2013 | 92 | 0.370 |
Why?
| | Pilot Projects | 4 | 2019 | 725 | 0.370 |
Why?
| | Lymphangioma, Cystic | 1 | 2011 | 9 | 0.370 |
Why?
| | Otitis Media with Effusion | 2 | 2025 | 20 | 0.360 |
Why?
| | Endothelium, Lymphatic | 1 | 2011 | 8 | 0.360 |
Why?
| | Antigens, CD | 1 | 2013 | 213 | 0.360 |
Why?
| | Clinical Competence | 3 | 2020 | 405 | 0.360 |
Why?
| | Delphi Technique | 5 | 2024 | 66 | 0.360 |
Why?
| | Laryngeal Diseases | 2 | 2010 | 11 | 0.360 |
Why?
| | Milk Proteins | 1 | 2012 | 77 | 0.360 |
Why?
| | Microtubule-Associated Proteins | 1 | 2011 | 61 | 0.360 |
Why?
| | Mouth | 2 | 2010 | 33 | 0.360 |
Why?
| | Papillomavirus Infections | 1 | 2013 | 170 | 0.350 |
Why?
| | Homeodomain Proteins | 1 | 2011 | 80 | 0.350 |
Why?
| | Tracheoesophageal Fistula | 2 | 2008 | 11 | 0.350 |
Why?
| | Laryngeal Mucosa | 1 | 2011 | 4 | 0.350 |
Why?
| | Combined Modality Therapy | 7 | 2018 | 641 | 0.350 |
Why?
| | Laryngeal Nerves | 1 | 2011 | 15 | 0.340 |
Why?
| | Nervous System Physiological Phenomena | 1 | 2010 | 9 | 0.340 |
Why?
| | Magnetic Resonance Angiography | 3 | 2018 | 67 | 0.340 |
Why?
| | Tumor Suppressor Proteins | 1 | 2011 | 127 | 0.340 |
Why?
| | Osseointegration | 3 | 2017 | 25 | 0.340 |
Why?
| | Severity of Illness Index | 6 | 2014 | 1045 | 0.340 |
Why?
| | Neuromuscular Diseases | 1 | 2011 | 31 | 0.330 |
Why?
| | Airway Obstruction | 3 | 2018 | 47 | 0.330 |
Why?
| | Hospitals, Special | 1 | 2010 | 9 | 0.330 |
Why?
| | Cholesteatoma, Middle Ear | 2 | 2009 | 32 | 0.330 |
Why?
| | Capillaries | 2 | 2022 | 53 | 0.320 |
Why?
| | Cheek | 1 | 2010 | 9 | 0.320 |
Why?
| | Lip | 1 | 2010 | 11 | 0.320 |
Why?
| | Tracheal Neoplasms | 1 | 2009 | 8 | 0.310 |
Why?
| | Immunohistochemistry | 4 | 2015 | 977 | 0.310 |
Why?
| | Fibrin Tissue Adhesive | 2 | 2008 | 13 | 0.310 |
Why?
| | Tympanic Membrane | 2 | 2025 | 41 | 0.310 |
Why?
| | Multiple Endocrine Neoplasia Type 2a | 1 | 2009 | 5 | 0.310 |
Why?
| | Tomography, X-Ray Computed | 7 | 2015 | 1140 | 0.310 |
Why?
| | Cicatrix | 2 | 2020 | 42 | 0.310 |
Why?
| | Carcinoma, Medullary | 1 | 2009 | 12 | 0.310 |
Why?
| | Proteus mirabilis | 1 | 2009 | 2 | 0.310 |
Why?
| | Proteus Infections | 1 | 2009 | 4 | 0.310 |
Why?
| | Bacteroidaceae Infections | 1 | 2009 | 4 | 0.310 |
Why?
| | Electrocoagulation | 2 | 2009 | 12 | 0.310 |
Why?
| | Bacteroides | 1 | 2009 | 9 | 0.310 |
Why?
| | Brain Abscess | 1 | 2009 | 10 | 0.300 |
Why?
| | Otitis Media, Suppurative | 1 | 2009 | 7 | 0.300 |
Why?
| | Cerebellar Diseases | 1 | 2009 | 17 | 0.300 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2009 | 33 | 0.300 |
Why?
| | Vomiting | 2 | 2021 | 71 | 0.300 |
Why?
| | Quality Improvement | 2 | 2021 | 226 | 0.300 |
Why?
| | Injections, Intralesional | 3 | 2021 | 32 | 0.290 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2021 | 182 | 0.290 |
Why?
| | Time Factors | 7 | 2020 | 2987 | 0.290 |
Why?
| | Risk Factors | 9 | 2020 | 3971 | 0.290 |
Why?
| | Child Development | 1 | 2010 | 208 | 0.290 |
Why?
| | Electrosurgery | 1 | 2008 | 9 | 0.280 |
Why?
| | Tracheotomy | 2 | 2019 | 15 | 0.280 |
Why?
| | Thyroid Neoplasms | 1 | 2009 | 111 | 0.280 |
Why?
| | Skin, Artificial | 1 | 2007 | 11 | 0.270 |
Why?
| | MicroRNAs | 2 | 2023 | 392 | 0.270 |
Why?
| | Hearing Loss, Unilateral | 3 | 2013 | 12 | 0.270 |
Why?
| | Fasciitis, Necrotizing | 1 | 2006 | 7 | 0.260 |
Why?
| | Atlanto-Axial Joint | 1 | 2006 | 7 | 0.260 |
Why?
| | Emphysema | 1 | 2006 | 14 | 0.260 |
Why?
| | Pediatrics | 3 | 2025 | 302 | 0.260 |
Why?
| | Diet | 1 | 2010 | 591 | 0.250 |
Why?
| | Arytenoid Cartilage | 2 | 2020 | 4 | 0.250 |
Why?
| | Recurrence | 6 | 2016 | 680 | 0.250 |
Why?
| | Photography | 2 | 2020 | 32 | 0.250 |
Why?
| | Disease Management | 3 | 2019 | 185 | 0.250 |
Why?
| | Otoscopes | 1 | 2025 | 5 | 0.240 |
Why?
| | Bone Conduction | 3 | 2017 | 26 | 0.240 |
Why?
| | Tinnitus | 1 | 2006 | 62 | 0.240 |
Why?
| | Transcranial Magnetic Stimulation | 1 | 2006 | 72 | 0.240 |
Why?
| | Esophagus | 3 | 2020 | 84 | 0.240 |
Why?
| | Esophagoscopy | 2 | 2020 | 29 | 0.240 |
Why?
| | Reoperation | 6 | 2014 | 463 | 0.240 |
Why?
| | Genetic Predisposition to Disease | 4 | 2019 | 525 | 0.230 |
Why?
| | Radiography | 2 | 2018 | 469 | 0.230 |
Why?
| | Branchial Region | 1 | 2024 | 4 | 0.220 |
Why?
| | Myringoplasty | 1 | 2024 | 6 | 0.220 |
Why?
| | Gene Expression Regulation | 2 | 2020 | 1004 | 0.220 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2024 | 56 | 0.220 |
Why?
| | Middle Aged | 16 | 2024 | 13133 | 0.220 |
Why?
| | Tympanic Membrane Perforation | 1 | 2024 | 20 | 0.210 |
Why?
| | Artificial Intelligence | 1 | 2025 | 124 | 0.210 |
Why?
| | Fellowships and Scholarships | 2 | 2016 | 123 | 0.210 |
Why?
| | Cross-Sectional Studies | 3 | 2022 | 1677 | 0.210 |
Why?
| | Diagnostic Imaging | 2 | 2017 | 171 | 0.200 |
Why?
| | Patient Selection | 2 | 2019 | 269 | 0.200 |
Why?
| | Single-Blind Method | 2 | 2020 | 118 | 0.200 |
Why?
| | Animals | 11 | 2019 | 13485 | 0.200 |
Why?
| | Internship and Residency | 2 | 2020 | 438 | 0.200 |
Why?
| | Cohort Studies | 5 | 2020 | 1576 | 0.200 |
Why?
| | Magnetic Resonance Imaging | 5 | 2015 | 1507 | 0.200 |
Why?
| | Antigens, Nuclear | 2 | 2013 | 24 | 0.200 |
Why?
| | Treatment Failure | 2 | 2016 | 117 | 0.200 |
Why?
| | Prognosis | 4 | 2018 | 2100 | 0.200 |
Why?
| | Transplantation, Heterologous | 2 | 2013 | 78 | 0.190 |
Why?
| | Mandible | 1 | 2023 | 25 | 0.190 |
Why?
| | Esthetics, Dental | 1 | 2022 | 6 | 0.190 |
Why?
| | Tracheal Stenosis | 2 | 2015 | 13 | 0.190 |
Why?
| | Vocal Cords | 1 | 2022 | 9 | 0.190 |
Why?
| | Mice, Nude | 2 | 2013 | 230 | 0.190 |
Why?
| | Middle Ear Ventilation | 2 | 2025 | 20 | 0.190 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2022 | 61 | 0.190 |
Why?
| | Disease Progression | 3 | 2011 | 870 | 0.190 |
Why?
| | Length of Stay | 2 | 2024 | 673 | 0.190 |
Why?
| | Immunoenzyme Techniques | 2 | 2013 | 134 | 0.190 |
Why?
| | Patient Readmission | 1 | 2024 | 249 | 0.190 |
Why?
| | Nevus, Blue | 1 | 2022 | 11 | 0.190 |
Why?
| | Respiratory Sounds | 2 | 2019 | 50 | 0.180 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2022 | 41 | 0.180 |
Why?
| | Databases, Factual | 1 | 2025 | 721 | 0.180 |
Why?
| | Case-Control Studies | 2 | 2017 | 1202 | 0.180 |
Why?
| | Rats, Sprague-Dawley | 5 | 2009 | 1558 | 0.170 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2013 | 1365 | 0.170 |
Why?
| | Operating Rooms | 1 | 2021 | 27 | 0.170 |
Why?
| | Nausea | 1 | 2021 | 44 | 0.170 |
Why?
| | Efficiency, Organizational | 1 | 2021 | 41 | 0.170 |
Why?
| | Air Microbiology | 1 | 2020 | 12 | 0.170 |
Why?
| | Mouth Mucosa | 1 | 2020 | 27 | 0.170 |
Why?
| | Thrombelastography | 1 | 2020 | 27 | 0.170 |
Why?
| | DiGeorge Syndrome | 1 | 2020 | 18 | 0.170 |
Why?
| | Hemostasis | 1 | 2020 | 54 | 0.160 |
Why?
| | Reference Values | 2 | 2011 | 316 | 0.160 |
Why?
| | Receptors, Notch | 1 | 2020 | 26 | 0.160 |
Why?
| | LIM Domain Proteins | 1 | 2020 | 8 | 0.160 |
Why?
| | Retinal Dehydrogenase | 1 | 2020 | 10 | 0.160 |
Why?
| | Myosin Type I | 1 | 2020 | 5 | 0.160 |
Why?
| | Diagnosis, Differential | 3 | 2019 | 1028 | 0.160 |
Why?
| | Antiporters | 1 | 2020 | 19 | 0.160 |
Why?
| | Hearing Loss, Conductive | 2 | 2011 | 55 | 0.160 |
Why?
| | Mastoid | 3 | 2009 | 51 | 0.160 |
Why?
| | Parasomnias | 1 | 2019 | 4 | 0.160 |
Why?
| | Cytoskeletal Proteins | 1 | 2020 | 47 | 0.160 |
Why?
| | Pain, Postoperative | 1 | 2021 | 169 | 0.160 |
Why?
| | Microsurgery | 2 | 2011 | 32 | 0.160 |
Why?
| | Analysis of Variance | 2 | 2014 | 558 | 0.160 |
Why?
| | Tertiary Care Centers | 1 | 2020 | 83 | 0.160 |
Why?
| | Surgical Wound Infection | 1 | 2020 | 118 | 0.160 |
Why?
| | Physician Assistants | 1 | 2019 | 19 | 0.160 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 42 | 0.160 |
Why?
| | Tetralogy of Fallot | 1 | 2020 | 83 | 0.160 |
Why?
| | Mitochondrial Proteins | 1 | 2020 | 91 | 0.150 |
Why?
| | Neovascularization, Pathologic | 1 | 2020 | 158 | 0.150 |
Why?
| | Endothelium, Vascular | 1 | 2021 | 263 | 0.150 |
Why?
| | Elastic Tissue | 1 | 2019 | 10 | 0.150 |
Why?
| | Ambulatory Care | 1 | 2021 | 238 | 0.150 |
Why?
| | Professional Role | 1 | 2019 | 79 | 0.150 |
Why?
| | Age Factors | 4 | 2013 | 1120 | 0.150 |
Why?
| | Microcirculation | 1 | 2019 | 64 | 0.150 |
Why?
| | Nurse Practitioners | 1 | 2019 | 42 | 0.150 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2019 | 65 | 0.150 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 202 | 0.150 |
Why?
| | Tryptases | 1 | 2018 | 4 | 0.150 |
Why?
| | Mice | 4 | 2017 | 5899 | 0.150 |
Why?
| | Sirolimus | 1 | 2019 | 72 | 0.150 |
Why?
| | Rats | 5 | 2009 | 3228 | 0.150 |
Why?
| | Dexamethasone | 1 | 2021 | 434 | 0.150 |
Why?
| | p120 GTPase Activating Protein | 1 | 2018 | 1 | 0.150 |
Why?
| | Fibrosis | 1 | 2019 | 198 | 0.140 |
Why?
| | Heart Defects, Congenital | 1 | 2024 | 615 | 0.140 |
Why?
| | Port-Wine Stain | 1 | 2018 | 14 | 0.140 |
Why?
| | Estrogen Receptor beta | 1 | 2018 | 54 | 0.140 |
Why?
| | Constriction, Pathologic | 1 | 2018 | 89 | 0.140 |
Why?
| | Cryosurgery | 1 | 2018 | 36 | 0.140 |
Why?
| | Airway Extubation | 1 | 2018 | 30 | 0.140 |
Why?
| | Random Allocation | 2 | 2009 | 286 | 0.140 |
Why?
| | Estrogen Receptor alpha | 1 | 2018 | 86 | 0.140 |
Why?
| | Protein Transport | 1 | 2018 | 172 | 0.140 |
Why?
| | Ultrasonography, Doppler | 1 | 2018 | 42 | 0.140 |
Why?
| | Optical Phenomena | 1 | 2017 | 5 | 0.140 |
Why?
| | Algorithms | 2 | 2025 | 673 | 0.140 |
Why?
| | Nanomedicine | 1 | 2017 | 15 | 0.140 |
Why?
| | Palatine Tonsil | 1 | 2017 | 11 | 0.140 |
Why?
| | Neovascularization, Physiologic | 2 | 2009 | 86 | 0.140 |
Why?
| | Cadaver | 1 | 2017 | 88 | 0.130 |
Why?
| | Faculty, Medical | 2 | 2019 | 92 | 0.130 |
Why?
| | beta-Thromboglobulin | 1 | 2017 | 1 | 0.130 |
Why?
| | Aggressive Periodontitis | 1 | 2017 | 1 | 0.130 |
Why?
| | Platelet Factor 4 | 1 | 2017 | 2 | 0.130 |
Why?
| | Chemokine CXCL5 | 1 | 2017 | 7 | 0.130 |
Why?
| | Constipation | 1 | 2017 | 38 | 0.130 |
Why?
| | Pressure | 1 | 2017 | 100 | 0.130 |
Why?
| | Angiotensinogen | 1 | 2017 | 12 | 0.130 |
Why?
| | Pathology, Surgical | 1 | 2017 | 23 | 0.130 |
Why?
| | Intubation, Intratracheal | 1 | 2018 | 116 | 0.130 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2017 | 27 | 0.130 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2018 | 83 | 0.130 |
Why?
| | Transcriptome | 1 | 2020 | 357 | 0.130 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2017 | 56 | 0.130 |
Why?
| | Diarrhea | 1 | 2017 | 95 | 0.130 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2018 | 178 | 0.130 |
Why?
| | Aged | 10 | 2022 | 10242 | 0.130 |
Why?
| | Child Behavior Disorders | 1 | 2017 | 77 | 0.130 |
Why?
| | Apoptosis | 3 | 2020 | 1120 | 0.130 |
Why?
| | Child Behavior | 1 | 2017 | 108 | 0.120 |
Why?
| | Food Hypersensitivity | 1 | 2017 | 100 | 0.120 |
Why?
| | Mitochondria | 1 | 2020 | 420 | 0.120 |
Why?
| | Serum | 1 | 2016 | 32 | 0.120 |
Why?
| | Tobacco Smoke Pollution | 1 | 2016 | 50 | 0.120 |
Why?
| | Drug Administration Schedule | 2 | 2013 | 370 | 0.120 |
Why?
| | Hearing Loss | 1 | 2017 | 95 | 0.120 |
Why?
| | Nasopharyngeal Diseases | 1 | 2015 | 2 | 0.120 |
Why?
| | Nasal Obstruction | 1 | 2015 | 11 | 0.110 |
Why?
| | Anticoagulants | 1 | 2018 | 276 | 0.110 |
Why?
| | Urinary Bladder | 1 | 2015 | 101 | 0.110 |
Why?
| | Inflammation | 1 | 2019 | 649 | 0.110 |
Why?
| | Bandages, Hydrocolloid | 1 | 2014 | 4 | 0.110 |
Why?
| | Gels | 1 | 2014 | 23 | 0.110 |
Why?
| | Endoscopy, Digestive System | 1 | 2014 | 51 | 0.110 |
Why?
| | North America | 1 | 2014 | 75 | 0.110 |
Why?
| | Biopsy, Needle | 1 | 2015 | 181 | 0.110 |
Why?
| | Early Diagnosis | 1 | 2014 | 84 | 0.110 |
Why?
| | Foreign Bodies | 2 | 2020 | 66 | 0.110 |
Why?
| | Sickness Impact Profile | 1 | 2014 | 28 | 0.110 |
Why?
| | Term Birth | 1 | 2013 | 17 | 0.110 |
Why?
| | Administration, Oral | 2 | 2018 | 455 | 0.110 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2013 | 38 | 0.100 |
Why?
| | Hospitals, University | 1 | 2013 | 73 | 0.100 |
Why?
| | Angiography | 3 | 2007 | 111 | 0.100 |
Why?
| | Polysomnography | 1 | 2013 | 76 | 0.100 |
Why?
| | Actins | 1 | 2013 | 112 | 0.100 |
Why?
| | Pregnancy | 1 | 2019 | 2642 | 0.090 |
Why?
| | Otologic Surgical Procedures | 2 | 2009 | 37 | 0.090 |
Why?
| | Bronchoscopy | 2 | 2010 | 75 | 0.090 |
Why?
| | Incidence | 2 | 2013 | 1096 | 0.090 |
Why?
| | Gene Transfer Techniques | 2 | 2002 | 44 | 0.090 |
Why?
| | Bone Neoplasms | 1 | 1994 | 188 | 0.090 |
Why?
| | Antiviral Agents | 1 | 2013 | 173 | 0.090 |
Why?
| | Lymphocele | 1 | 2011 | 7 | 0.090 |
Why?
| | Tissue Survival | 1 | 2011 | 10 | 0.090 |
Why?
| | Hearing Loss, Sensorineural | 1 | 2013 | 80 | 0.090 |
Why?
| | Statistics, Nonparametric | 2 | 2014 | 199 | 0.090 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 46 | 0.090 |
Why?
| | Tissue Culture Techniques | 1 | 2011 | 42 | 0.090 |
Why?
| | Ultrasonography, Interventional | 1 | 2012 | 137 | 0.090 |
Why?
| | Internet | 1 | 2014 | 262 | 0.090 |
Why?
| | Education, Medical, Graduate | 1 | 2014 | 217 | 0.090 |
Why?
| | Arkansas | 3 | 2016 | 2013 | 0.090 |
Why?
| | Liver | 1 | 2017 | 1150 | 0.090 |
Why?
| | Lymphocytosis | 1 | 2011 | 4 | 0.090 |
Why?
| | Laryngeal Edema | 1 | 2011 | 5 | 0.090 |
Why?
| | Genetic Therapy | 2 | 2002 | 127 | 0.090 |
Why?
| | Brain | 1 | 2019 | 1337 | 0.090 |
Why?
| | Hypertrophy | 1 | 2011 | 53 | 0.090 |
Why?
| | Nutritional Support | 1 | 2010 | 31 | 0.080 |
Why?
| | Infant, Premature | 1 | 2013 | 327 | 0.080 |
Why?
| | Lip Neoplasms | 1 | 2010 | 3 | 0.080 |
Why?
| | Burns | 2 | 2002 | 163 | 0.080 |
Why?
| | Auditory Threshold | 1 | 2010 | 54 | 0.080 |
Why?
| | Tracheal Diseases | 1 | 2010 | 13 | 0.080 |
Why?
| | United States | 5 | 2025 | 5215 | 0.080 |
Why?
| | Hospitals, Teaching | 1 | 2010 | 52 | 0.080 |
Why?
| | Thyroglossal Cyst | 1 | 2009 | 4 | 0.080 |
Why?
| | Tongue Diseases | 1 | 2009 | 6 | 0.080 |
Why?
| | Medical Records | 1 | 2010 | 83 | 0.080 |
Why?
| | Vincristine | 1 | 2009 | 89 | 0.080 |
Why?
| | Calcitonin | 1 | 2009 | 30 | 0.080 |
Why?
| | Blood Flow Velocity | 2 | 2020 | 97 | 0.080 |
Why?
| | Sensory Thresholds | 1 | 2009 | 17 | 0.080 |
Why?
| | Granulation Tissue | 1 | 2009 | 10 | 0.080 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2009 | 71 | 0.080 |
Why?
| | Rhinitis | 1 | 2009 | 28 | 0.080 |
Why?
| | Lymphotoxin-alpha | 1 | 2009 | 7 | 0.080 |
Why?
| | Societies, Medical | 2 | 2025 | 200 | 0.070 |
Why?
| | Neoplasm Invasiveness | 1 | 2010 | 278 | 0.070 |
Why?
| | Physical Examination | 1 | 2009 | 98 | 0.070 |
Why?
| | Mucous Membrane | 1 | 2009 | 33 | 0.070 |
Why?
| | Sinusitis | 1 | 2009 | 42 | 0.070 |
Why?
| | Turner Syndrome | 1 | 2008 | 15 | 0.070 |
Why?
| | Thyroidectomy | 1 | 2009 | 61 | 0.070 |
Why?
| | Biopsy, Fine-Needle | 1 | 2009 | 104 | 0.070 |
Why?
| | Infusions, Intravenous | 1 | 2009 | 212 | 0.070 |
Why?
| | Transplantation, Homologous | 1 | 2009 | 151 | 0.070 |
Why?
| | X-Ray Intensifying Screens | 1 | 2008 | 3 | 0.070 |
Why?
| | Ear Diseases | 1 | 2008 | 28 | 0.070 |
Why?
| | Burns, Electric | 1 | 2008 | 2 | 0.070 |
Why?
| | Chi-Square Distribution | 1 | 2009 | 292 | 0.070 |
Why?
| | Shock, Septic | 1 | 2009 | 70 | 0.070 |
Why?
| | Fires | 1 | 2008 | 15 | 0.070 |
Why?
| | Suction | 1 | 2008 | 22 | 0.070 |
Why?
| | Gastrointestinal Hemorrhage | 2 | 2022 | 91 | 0.070 |
Why?
| | Cerebral Angiography | 1 | 2008 | 90 | 0.070 |
Why?
| | Intracranial Aneurysm | 1 | 2008 | 46 | 0.070 |
Why?
| | Sleep Apnea Syndromes | 1 | 2008 | 33 | 0.070 |
Why?
| | Photomicrography | 1 | 2007 | 6 | 0.070 |
Why?
| | Factor VII | 1 | 2007 | 3 | 0.070 |
Why?
| | Hospitals, Pediatric | 2 | 2019 | 241 | 0.070 |
Why?
| | Neoplasm Staging | 1 | 2010 | 768 | 0.070 |
Why?
| | Mouth Floor | 1 | 2007 | 5 | 0.070 |
Why?
| | Postoperative Care | 1 | 2008 | 104 | 0.070 |
Why?
| | Polyvinyl Alcohol | 1 | 2007 | 10 | 0.070 |
Why?
| | Collateral Circulation | 1 | 2007 | 38 | 0.060 |
Why?
| | Biocompatible Materials | 1 | 2007 | 67 | 0.060 |
Why?
| | Intraoperative Complications | 1 | 2008 | 113 | 0.060 |
Why?
| | Auditory Cortex | 1 | 2006 | 19 | 0.060 |
Why?
| | Patient Satisfaction | 1 | 2008 | 287 | 0.060 |
Why?
| | Therapy, Computer-Assisted | 1 | 2006 | 33 | 0.060 |
Why?
| | Thalamus | 1 | 2006 | 35 | 0.060 |
Why?
| | Arousal | 1 | 2006 | 103 | 0.060 |
Why?
| | Phenotype | 2 | 2019 | 792 | 0.060 |
Why?
| | Swine | 1 | 2007 | 428 | 0.060 |
Why?
| | Psychomotor Performance | 1 | 2006 | 127 | 0.060 |
Why?
| | Otoscopy | 1 | 2025 | 9 | 0.060 |
Why?
| | Reaction Time | 1 | 2006 | 209 | 0.060 |
Why?
| | Attention | 1 | 2006 | 168 | 0.060 |
Why?
| | Sensitivity and Specificity | 2 | 2025 | 871 | 0.060 |
Why?
| | Preoperative Care | 1 | 2007 | 173 | 0.060 |
Why?
| | Radiopharmaceuticals | 1 | 2006 | 198 | 0.060 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2006 | 181 | 0.060 |
Why?
| | Fibroblast Growth Factors | 2 | 2002 | 48 | 0.060 |
Why?
| | Chronic Disease | 3 | 2016 | 579 | 0.060 |
Why?
| | DNA, Complementary | 2 | 2002 | 129 | 0.060 |
Why?
| | Emergency Service, Hospital | 1 | 2009 | 521 | 0.060 |
Why?
| | Advisory Committees | 1 | 2025 | 74 | 0.060 |
Why?
| | Positron-Emission Tomography | 1 | 2006 | 297 | 0.060 |
Why?
| | Craniofacial Abnormalities | 1 | 2024 | 27 | 0.050 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2024 | 102 | 0.050 |
Why?
| | Mice, Inbred C57BL | 1 | 2009 | 1888 | 0.050 |
Why?
| | Fetus | 2 | 2021 | 191 | 0.050 |
Why?
| | Mutation | 2 | 2019 | 1331 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2009 | 816 | 0.050 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2023 | 84 | 0.050 |
Why?
| | Growth Differentiation Factor 2 | 1 | 2022 | 6 | 0.050 |
Why?
| | Otitis Media | 2 | 2016 | 36 | 0.050 |
Why?
| | Transforming Growth Factor beta | 1 | 2022 | 136 | 0.050 |
Why?
| | Registries | 1 | 2025 | 638 | 0.040 |
Why?
| | alpha-Fetoproteins | 1 | 2001 | 12 | 0.040 |
Why?
| | Esophagoscopes | 1 | 2020 | 1 | 0.040 |
Why?
| | Blood Coagulation Tests | 1 | 2020 | 18 | 0.040 |
Why?
| | Blood Coagulation | 1 | 2020 | 64 | 0.040 |
Why?
| | Gastrostomy | 1 | 2020 | 55 | 0.040 |
Why?
| | Ligands | 1 | 2020 | 205 | 0.040 |
Why?
| | Exhalation | 1 | 2019 | 19 | 0.040 |
Why?
| | Embryonic Development | 1 | 2019 | 19 | 0.040 |
Why?
| | Hepatitis C | 1 | 2001 | 80 | 0.040 |
Why?
| | Sheep | 1 | 2000 | 89 | 0.040 |
Why?
| | Risk | 1 | 2020 | 315 | 0.040 |
Why?
| | Genetic Loci | 1 | 2019 | 46 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2019 | 97 | 0.040 |
Why?
| | Vasodilation | 1 | 2000 | 99 | 0.040 |
Why?
| | Angiogenesis Inhibitors | 1 | 2020 | 183 | 0.040 |
Why?
| | Income | 1 | 2019 | 106 | 0.040 |
Why?
| | Genetic Association Studies | 1 | 2019 | 124 | 0.040 |
Why?
| | Syndrome | 1 | 2019 | 247 | 0.040 |
Why?
| | Alcohol Drinking | 1 | 2001 | 235 | 0.040 |
Why?
| | Hemorrhage | 1 | 2020 | 225 | 0.040 |
Why?
| | Gene Expression | 1 | 2021 | 618 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2020 | 726 | 0.040 |
Why?
| | Comparative Genomic Hybridization | 1 | 2018 | 37 | 0.040 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2018 | 8 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2001 | 243 | 0.040 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2001 | 208 | 0.040 |
Why?
| | Fibrinogen | 1 | 2018 | 31 | 0.040 |
Why?
| | Equipment Design | 2 | 2010 | 287 | 0.040 |
Why?
| | Lymphatic System | 1 | 2018 | 13 | 0.030 |
Why?
| | Peptic Ulcer Hemorrhage | 1 | 1997 | 4 | 0.030 |
Why?
| | Tertiary Healthcare | 1 | 2017 | 15 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2020 | 423 | 0.030 |
Why?
| | Tissue Adhesives | 1 | 1997 | 15 | 0.030 |
Why?
| | Linkage Disequilibrium | 1 | 2017 | 41 | 0.030 |
Why?
| | Catheterization | 2 | 1996 | 94 | 0.030 |
Why?
| | Quantitative Trait Loci | 1 | 2017 | 52 | 0.030 |
Why?
| | Liver Neoplasms | 1 | 2001 | 341 | 0.030 |
Why?
| | Polyethylene Glycols | 1 | 1997 | 93 | 0.030 |
Why?
| | Haplotypes | 1 | 2017 | 95 | 0.030 |
Why?
| | Transcription Factors | 1 | 2020 | 570 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2017 | 271 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2017 | 184 | 0.030 |
Why?
| | Leg | 1 | 1996 | 122 | 0.030 |
Why?
| | Genotype | 1 | 2017 | 563 | 0.030 |
Why?
| | Arterial Occlusive Diseases | 1 | 1996 | 80 | 0.030 |
Why?
| | Triage | 1 | 2016 | 66 | 0.030 |
Why?
| | Pain | 1 | 2018 | 373 | 0.030 |
Why?
| | Thrombolytic Therapy | 1 | 1996 | 113 | 0.030 |
Why?
| | Fibrinolytic Agents | 1 | 1996 | 131 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2016 | 601 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 563 | 0.030 |
Why?
| | Quality-Adjusted Life Years | 1 | 2015 | 67 | 0.030 |
Why?
| | Software | 1 | 2017 | 281 | 0.030 |
Why?
| | Patient-Centered Care | 1 | 2016 | 141 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2017 | 506 | 0.030 |
Why?
| | Portasystemic Shunt, Surgical | 1 | 1994 | 6 | 0.030 |
Why?
| | Esophageal and Gastric Varices | 1 | 1994 | 18 | 0.030 |
Why?
| | Job Application | 1 | 2014 | 12 | 0.030 |
Why?
| | Hypertension, Portal | 1 | 1994 | 23 | 0.030 |
Why?
| | Aged, 80 and over | 3 | 2015 | 3449 | 0.030 |
Why?
| | Logistic Models | 1 | 2016 | 930 | 0.030 |
Why?
| | Personnel Selection | 1 | 2014 | 25 | 0.030 |
Why?
| | Personal Satisfaction | 1 | 2014 | 74 | 0.030 |
Why?
| | Carcinoma, Renal Cell | 1 | 1994 | 112 | 0.020 |
Why?
| | Temporal Bone | 1 | 2013 | 38 | 0.020 |
Why?
| | Patient Care Team | 1 | 2015 | 267 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 498 | 0.020 |
Why?
| | Patient Admission | 1 | 2013 | 80 | 0.020 |
Why?
| | Kidney Neoplasms | 1 | 1994 | 181 | 0.020 |
Why?
| | Fibroblast Growth Factor 7 | 2 | 2002 | 5 | 0.020 |
Why?
| | Oximetry | 1 | 2013 | 63 | 0.020 |
Why?
| | Program Evaluation | 1 | 2014 | 351 | 0.020 |
Why?
| | Liposomes | 2 | 2002 | 53 | 0.020 |
Why?
| | Liver Transplantation | 1 | 1994 | 171 | 0.020 |
Why?
| | Decision Making | 1 | 2014 | 273 | 0.020 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2002 | 140 | 0.020 |
Why?
| | Transfection | 2 | 2002 | 365 | 0.020 |
Why?
| | Cell Division | 2 | 2002 | 288 | 0.020 |
Why?
| | Electrocardiography | 1 | 2013 | 273 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2013 | 288 | 0.020 |
Why?
| | Stents | 1 | 1994 | 368 | 0.020 |
Why?
| | Survival Rate | 2 | 2008 | 944 | 0.020 |
Why?
| | Blood Pressure | 1 | 2013 | 525 | 0.020 |
Why?
| | Lymphoid Tissue | 1 | 2010 | 23 | 0.020 |
Why?
| | Suture Anchors | 1 | 2010 | 11 | 0.020 |
Why?
| | Fiber Optic Technology | 1 | 2010 | 14 | 0.020 |
Why?
| | Blood Glucose | 1 | 2013 | 483 | 0.020 |
Why?
| | Safety | 1 | 2010 | 78 | 0.020 |
Why?
| | Prolapse | 1 | 2009 | 6 | 0.020 |
Why?
| | Skin Diseases, Infectious | 1 | 1968 | 8 | 0.020 |
Why?
| | Eczema | 1 | 1968 | 12 | 0.020 |
Why?
| | Ear, Middle | 1 | 2008 | 19 | 0.020 |
Why?
| | Demography | 1 | 2009 | 92 | 0.020 |
Why?
| | Electric Power Supplies | 1 | 2008 | 1 | 0.020 |
Why?
| | Equipment Failure Analysis | 1 | 2008 | 44 | 0.020 |
Why?
| | Acute Disease | 1 | 2009 | 384 | 0.020 |
Why?
| | Drainage | 1 | 2008 | 88 | 0.020 |
Why?
| | Factor VIIa | 1 | 2007 | 8 | 0.020 |
Why?
| | Postoperative Hemorrhage | 1 | 2007 | 54 | 0.020 |
Why?
| | Brain Damage, Chronic | 1 | 1986 | 14 | 0.020 |
Why?
| | Angiomatosis | 1 | 1965 | 7 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2007 | 490 | 0.010 |
Why?
| | Anemia | 1 | 1965 | 75 | 0.010 |
Why?
| | Sex Factors | 2 | 2001 | 735 | 0.010 |
Why?
| | Skin Physiological Phenomena | 1 | 2002 | 16 | 0.010 |
Why?
| | Epidermis | 1 | 2002 | 32 | 0.010 |
Why?
| | Regeneration | 1 | 2002 | 79 | 0.010 |
Why?
| | Germany | 1 | 2001 | 26 | 0.010 |
Why?
| | Epidemiologic Studies | 1 | 2001 | 23 | 0.010 |
Why?
| | Age of Onset | 1 | 2001 | 109 | 0.010 |
Why?
| | Endothelin-1 | 1 | 2000 | 34 | 0.010 |
Why?
| | Nitric Oxide Synthase | 1 | 2000 | 72 | 0.010 |
Why?
| | Hemodynamics | 1 | 2000 | 235 | 0.010 |
Why?
| | Blood Vessel Prosthesis | 1 | 1996 | 85 | 0.010 |
Why?
| | Hepatic Veins | 1 | 1994 | 5 | 0.010 |
Why?
| | Portacaval Shunt, Surgical | 1 | 1994 | 11 | 0.010 |
Why?
| | Portal Vein | 1 | 1994 | 27 | 0.010 |
Why?
| | Cause of Death | 1 | 1994 | 157 | 0.010 |
Why?
| | Germany, East | 1 | 1968 | 4 | 0.000 |
Why?
| | Dermatitis, Seborrheic | 1 | 1968 | 4 | 0.000 |
Why?
| | Dermatomycoses | 1 | 1968 | 16 | 0.000 |
Why?
| | Seasons | 1 | 1968 | 95 | 0.000 |
Why?
| | Dermatitis, Atopic | 1 | 1968 | 39 | 0.000 |
Why?
| | Personality Development | 1 | 1986 | 5 | 0.000 |
Why?
| | Education, Special | 1 | 1986 | 9 | 0.000 |
Why?
| | Social Adjustment | 1 | 1986 | 29 | 0.000 |
Why?
| | Psychological Tests | 1 | 1986 | 50 | 0.000 |
Why?
| | Intelligence | 1 | 1986 | 54 | 0.000 |
Why?
| | Intellectual Disability | 1 | 1986 | 127 | 0.000 |
Why?
| | Skin Diseases | 1 | 1965 | 118 | 0.000 |
Why?
| | Gastrointestinal Diseases | 1 | 1965 | 126 | 0.000 |
Why?
| | Brain Injuries | 1 | 1986 | 158 | 0.000 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 1986 | 177 | 0.000 |
Why?
|
|
Richter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|